OraSure Technologies (NASDAQ:OSUR) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $3.00.

OraSure Technologies Stock Performance

OraSure Technologies stock opened at $3.97 on Friday. The stock has a 50-day simple moving average of $4.08 and a 200 day simple moving average of $3.33. The stock has a market capitalization of $273.33 million, a P/E ratio of -3.82 and a beta of 1.01. OraSure Technologies has a 52 week low of $2.08 and a 52 week high of $4.58.

Insider Activity at OraSure Technologies

In other news, Director Steven Kyle Boyd bought 25,000 shares of the stock in a transaction dated Thursday, May 14th. The shares were bought at an average price of $2.99 per share, for a total transaction of $74,750.00. Following the completion of the purchase, the director owned 113,462 shares in the company, valued at approximately $339,251.38. This trade represents a 28.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.

Institutional Trading of OraSure Technologies

Several institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its position in OraSure Technologies by 71.1% during the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock worth $6,781,000 after buying an additional 878,151 shares during the period. Geode Capital Management LLC boosted its position in shares of OraSure Technologies by 6.4% in the second quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier’s stock valued at $5,611,000 after acquiring an additional 112,851 shares during the period. Cannell Capital LLC boosted its position in shares of OraSure Technologies by 33.7% in the second quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock valued at $5,595,000 after acquiring an additional 470,536 shares during the period. Kotler Kevin bought a new stake in shares of OraSure Technologies in the fourth quarter valued at about $4,359,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of OraSure Technologies by 9.5% in the second quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock valued at $5,371,000 after acquiring an additional 154,985 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.